Tags : Peripheral Arterial Disease

Philips Reports Results of Stellarex .035 Low-Dose Drug-Coated Balloon in

Tuba Khan May 30, 2019

Shots: The ILLUMENATE & ILLUMENATE EU RCT studies results involve assessing of Stellarex .035 DCB vs uncoated balloons in patients with the peripheral arterial disease for 3yrs. The ILLUMENATE & […]readmore

Tags : Peripheral Arterial Disease

Philips Reports Results of Stellarex .035 Low-Dose Drug-Coated Balloon in

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Peripheral Arterial Disease

﻿Philips Reports Results of Stellarex .035 Low-Dose Drug-Coated Balloon in

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Philips Reports Results of Stellarex .035 Low-Dose Drug-Coated Balloon in